

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
10 November 2022 (10.11.2022)



(10) International Publication Number
WO 2022/233957 A1

(51) International Patent Classification:
C07K 16/28 (2006.01)

(21) International Application Number:
PCT/EP2022/062018

(22) International Filing Date:
04 May 2022 (04.05.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
21172352.3 05 May 2021 (05.05.2021) EP
63/184,698 05 May 2021 (05.05.2021) US

(71) Applicant: IMMATICS BIOTECHNOLOGIES GMBH
[DE/DE]; Paul-Ehrlich-Str. 15, 72076 Tübingen (DE).

(72) Inventors: BUNK, Sebastian; c/o Immatix Biotechnologies GmbH, Paul-Ehrlich-Str. 15, 72076 Tübingen (DE). HOFMANN, Martin; c/o Immatix Biotechnologies GmbH, Paul-Ehrlich-Str. 15, 72076 Tübingen (DE). UNVERDORBEN, Felix; c/o Immatix Biotechnologies GmbH, Paul-Ehrlich-Str. 15, 72076 Tübingen (DE).

(74) Agent: ZWICKER, Jörk; Zwicker Schnappauf & Partner Patentanwälte PartG mbB, Hansastr. 32, 80686 München (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))



WO 2022/233957 A1

(54) Title: BMA031 ANTIGEN BINDING POLYPEPTIDES

(57) Abstract: The present invention relates to an antigen binding polypeptide specifically binding to an α/β T cell receptor (TCR)/cluster of differentiation 3 (CD3) complex. The present invention further provides a nucleic acid comprising a sequence encoding for the antigen binding polypeptide or a vector comprising said nucleic acid. The invention further relates to recombinant host cells comprising the antigen binding polypeptide, and to pharmaceutical compositions comprising the antigen binding polypeptide, the nucleic acid, the vector and/or the host cell. The present invention further relates to the antigen binding polypeptide, the nucleic acid, the vector, the host cell or the pharmaceutical composition for use in medicine, in particular for use in the diagnosis, prevention, and/or treatment of a proliferative disease. The invention also relates to a method for improving or maintaining the binding and/or improving the stability of the antigen binding polypeptides. The invention also relates to a method for detecting, determining or enriching T cells expressing the α/β TCR/CD3 complex.